I think management have done a great job this calendar year with multiple milestones hit:
- Products available on the market generating revenue.
- Multiple international distribution agreements signed
- Revenue and expansion happening from Non-Pharma activities
- Further revenue generated from CannaGlobal.
As much as there have been delays and unfortunate outcomes in the past, many were not actually an issue with MXC's end, including the VC deal (it was VC who failed to meet their commitment).
The reality is we are building a pharmaceutical company, which is no easy task and the amount of effort/time/research required to get a product registered is monumental. We are well on our way and well ahead of competitors. With Malta also coming up, I am optimistic for the future of this company.
Many downrampers here don't have a clue how business works. If you have no emotional control or patience, don't invest in this end of the market.
Ann: Material Revenues Confirmed from Non-Pharma Business Units, page-61
-
- There are more pages in this discussion • 47 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
